Abstract
BackgroundWith the progressive move of chimeric antigen receptor (CAR) T-cell therapy as a first-line treatment option for patients with B-cell malignancies, multiple efforts are being made to extend this therapy...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
